pubmed.ncbi.nlm.nih.gov

Crohn's disease - PubMed

  • ️Wed Jan 01 2020

Review

Crohn's disease

Giulia Roda et al. Nat Rev Dis Primers. 2020.

Erratum in

  • Publisher Correction: Crohn's disease.

    Roda G, Ng SC, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Roda G, et al. Nat Rev Dis Primers. 2020 Apr 6;6(1):26. doi: 10.1038/s41572-020-0172-2. Nat Rev Dis Primers. 2020. PMID: 32251284

  • Author Correction: Crohn's disease.

    Roda G, Ng SC, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Roda G, et al. Nat Rev Dis Primers. 2020 May 20;6(1):42. doi: 10.1038/s41572-020-0183-z. Nat Rev Dis Primers. 2020. PMID: 32433463

  • Author Correction: Crohn's disease.

    Roda G, Ng SC, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Roda G, et al. Nat Rev Dis Primers. 2020 Jun 19;6(1):51. doi: 10.1038/s41572-020-0193-x. Nat Rev Dis Primers. 2020. PMID: 32561754

Abstract

Crohn's disease is an inflammatory bowel disease that is characterized by chronic inflammation of any part of the gastrointestinal tract, has a progressive and destructive course and is increasing in incidence worldwide. Several factors have been implicated in the cause of Crohn's disease, including a dysregulated immune system, an altered microbiota, genetic susceptibility and environmental factors, but the cause of the disease remains unknown. The onset of the disease at a young age in most cases necessitates prompt but long-term treatment to prevent disease flares and disease progression with intestinal complications. Thus, earlier, more aggressive treatment with biologic therapies or novel small molecules could profoundly change the natural history of the disease and decrease complications and the need for hospitalization and surgery. Although less invasive biomarkers are in development, diagnosis still relies on endoscopy and histological assessment of biopsy specimens. Crohn's disease is a complex disease, and treatment should be personalized to address the underlying pathogenetic mechanism. In the future, disease management might rely on severity scores that incorporate prognostic factors, bowel damage assessment and non-invasive close monitoring of disease activity to reduce the severity of complications.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769–2778 (2018). This study provides a comprehensive analysis of the global IBD epidemiology. - PubMed - DOI
    1. Torres, J., Mehandru, S., Colombel, J.-F. & Peyrin-Biroulet, L. Crohn’s disease. Lancet 389, 1741–1755 (2017). - PubMed - DOI
    1. Thia, K. T., Sandborn, W. J., Harmsen, W. S., Zinsmeister, A. R. & Loftus, E. V. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 139, 1147–1155 (2010). - PubMed - PMC - DOI
    1. Fiorino, G., Bonifacio, C., Peyrin-Biroulet, L. & Danese, S. Preventing collateral damage in Crohn’s disease: the Lémann index. J. Crohns Colitis 10, 495–500 (2016). This study clearly shows the importance of assessing bowel damage in a very early inflammatory stage of CD. The authors demonstrate that the presence of bowel damage in early CD is associated with a worse outcome. - PubMed - PMC - DOI
    1. Zeng, Z. et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong province, China: a prospective population-based study. J. Gastroenterol. Hepatol. 28, 1148–1153 (2013). - PubMed - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources